Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Oral AMN107 in Adults With Chronic Myelogenous Leukemia Resistant and/or Intolerant to Imatinib Mesylate Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Imatinib - resistant or - intolerant Philadelphia chromosome-positive CML in blast crisis, accelerated or chronic phase~* Males or females ≥ 18 years of age~Exclusion Criteria:~* Impaired cardiac function~* Acute or chronic liver or renal disease~* Use of therapeutic coumadin~* Central nervous system (CNS) infiltration~Additional protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AMN107 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).